1 Min Read
Oct 3 (Reuters) - Castle Creek Pharmaceuticals
* Castle Creek Pharmaceuticals announces late-breaking results at EADV of phase 2 topical diacerein 1% data in patients with epidermolysis bullosa simplex (ebs) Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.